Why the study?
To achieve and maintain global polio eradication and minimise vaccine-derived poliovirus outbreaks, novel monovalent oral type-2 poliovirus candidates with greater genetic stability and lower reversion risk were tested in a first-in-human study.
Are novel monovalent oral type-2 poliovirus vaccine candidates safe and immunogenic in healthy adults previously vaccinated with IPV?
Are novel monovalent oral type-2 poliovirus vaccine candidates safe and immunogenic in healthy adults previously vaccinated with IPV?
Two novel OPV2 candidates were safe, immunogenic, and showed genetic stability in IPV-immunized adults, supporting their potential use in maintaining global polio eradication.
No takes yet. Share an insight, caveat, or question.
Supports advancement to eradication trials; extends RCT safety and immunogenicity data to IPV-primed adults.
Damme et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: